Every 424B that Twist Bioscience (TWST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TWST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TWST filings page.
Twist Bioscience Corporation (TWST) has filed a prospectus supplement registering for resale up to 35,114 shares of common stock issuable to a selling securityholder, Invenra Inc., under a Stock Purchase Agreement and related Registration Rights Agreement. These shares may be sold from time to time in various types of brokerage or privately negotiated transactions. Twist will bear registration-related expenses but will not receive any proceeds from the selling securityholder’s sales. As of March 31, 2026, Twist had 62,154,412 shares of common stock outstanding, separate from this resale amount. The filing also renews registration after a prior automatic shelf on Form S-3 expired under Rule 415(a)(5).
Twist Bioscience Corporation is conducting a primary offering of 3,125,000 shares of common stock at $96.00 per share, for gross proceeds of $300,000,000 and estimated net proceeds of $284.3 million after underwriting fees and expenses. Underwriters have a 30‑day option to buy up to 468,750 additional shares. Shares outstanding will be 65,799,150 after the offering, excluding the option.
Management plans to use the cash, together with existing resources, to fund research and development, expand manufacturing capacity, support product offerings, and for working capital and other general corporate purposes, with potential but uncommitted in‑licensing or acquisitions. For the quarter ended June 30, 2026, Twist reported $118.4 million in revenue, a $35.1 million net loss (or $0.56 per diluted share), and adjusted EBITDA of $(11.3) million.
The company estimates an immediate increase in net tangible book value from $5.60 to $9.65 per share, implying $86.35 per‑share dilution to new investors at the offering price. Existing equity plans and an unused $200.0 million at‑the‑market program represent additional potential future issuances.
Twist Bioscience Corporation is offering $250.0 million of shares of its common stock in a primary underwritten offering, with an option for underwriters to purchase up to an additional $37.5 million of common stock for 30 days. The stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist expects to use the net proceeds, together with existing cash, cash equivalents and short-term investments, to fund research and development, expand manufacturing capacity and product offerings, and for working capital and other general corporate purposes, with potential in-licensing or acquisitions. As of June 30, 2026, net tangible book value was $350.8 million, or $5.60 per share, based on 62,674,150 shares outstanding. For the quarter ended June 30, 2026, revenue was $118.4 million, with a net loss of $35.1 million and adjusted EBITDA of $(11.3) million.
Twist Bioscience Corporation has filed a prospectus supplement registering up to 632,328 shares of common stock for resale by existing selling securityholders. These shares are issuable under Stock Purchase Agreements dated February 11, 2026, and may be sold over time in various types of negotiated or market transactions.
The selling securityholders, including Invenra Inc. and other smaller holders, will receive all proceeds from any share sales, while Twist will receive no proceeds from these resales and will only cover registration-related expenses. The company’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.